These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 27435702)

  • 1. Long-Term Safety Follow-Up of Subjects Previously Treated with Non-Replicating Retroviral Vector-Based Gene Therapies.
    Mohanlal R; Qiu Y; Zheng M; Mirkou A; Sridharan K; Keir C
    Mol Diagn Ther; 2016 Dec; 20(6):591-602. PubMed ID: 27435702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology Patients.
    Marcucci KT; Jadlowsky JK; Hwang WT; Suhoski-Davis M; Gonzalez VE; Kulikovskaya I; Gupta M; Lacey SF; Plesa G; Chew A; Melenhorst JJ; Levine BL; June CH
    Mol Ther; 2018 Jan; 26(1):269-279. PubMed ID: 29203150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of PCR and ELISA assays for screening clinical trial subjects for replication-competent retrovirus.
    Martineau D; Klump WM; McCormack JE; DePolo NJ; Kamantigue E; Petrowski M; Hanlon J; Jolly DJ; Mento SJ; Sajjadi N
    Hum Gene Ther; 1997 Jul; 8(10):1231-41. PubMed ID: 9215740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trial watch: Self-inactivating gene-therapy vector alleviates safety concerns.
    Cully M
    Nat Rev Drug Discov; 2014 Dec; 13(12):879. PubMed ID: 25394873
    [No Abstract]   [Full Text] [Related]  

  • 5. Biosafety of onco-retroviral vectors.
    VandenDriessche T; Collen D; Chuah MK
    Curr Gene Ther; 2003 Dec; 3(6):501-15. PubMed ID: 14683449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrovirus-induced oncogenesis and safety of retroviral vectors.
    Nair V
    Curr Opin Mol Ther; 2008 Oct; 10(5):431-8. PubMed ID: 18830918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Replication-competent vectors and empty virus-like particles: new retroviral vector designs for cancer gene therapy or vaccines.
    Dalba C; Bellier B; Kasahara N; Klatzmann D
    Mol Ther; 2007 Mar; 15(3):457-66. PubMed ID: 17245356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Replication competent retrovirus testing (RCR) in the National Gene Vector Biorepository: No evidence of RCR in 1,595 post-treatment peripheral blood samples obtained from 60 clinical trials.
    Cornetta K; Yao J; House K; Duffy L; Adusumilli PS; Beyer R; Booth C; Brenner M; Curran K; Grilley B; Heslop H; Hinrichs CS; Kaplan RN; Kiem HP; Kochenderfer J; Kohn DB; Mailankody S; Norberg SM; O'Cearbhaill RE; Pappas J; Park J; Ramos C; Ribas A; Rivière I; Rosenberg SA; Sauter C; Shah NN; Slovin SF; Thrasher A; Williams DA; Lin TY
    Mol Ther; 2023 Mar; 31(3):801-809. PubMed ID: 36518078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of recommendations for replication-competent retrovirus testing associated with use of retroviral vectors.
    Wilson CA; Ng TH; Miller AE
    Hum Gene Ther; 1997 May; 8(7):869-74. PubMed ID: 9143913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene therapy studies in a canine model of X-linked severe combined immunodeficiency.
    Felsburg PJ; De Ravin SS; Malech HL; Sorrentino BP; Burtner C; Kiem HP
    Hum Gene Ther Clin Dev; 2015 Mar; 26(1):50-6. PubMed ID: 25603151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation.
    Hesdorffer C; Ayello J; Ward M; Kaubisch A; Vahdat L; Balmaceda C; Garrett T; Fetell M; Reiss R; Bank A; Antman K
    J Clin Oncol; 1998 Jan; 16(1):165-72. PubMed ID: 9440739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant retroviral vector interferes with the detection of amphotropic replication competent retrovirus in standard culture assays.
    Printz M; Reynolds J; Mento SJ; Jolly D; Kowal K; Sajjadi N
    Gene Ther; 1995 Mar; 2(2):143-50. PubMed ID: 7719931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction of a retroviral vector production system with the minimum possibility of a homologous recombination.
    Yu SS; Han E; Hong Y; Lee JT; Kim S; Kim S
    Gene Ther; 2003 Apr; 10(8):706-11. PubMed ID: 12692599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of retroviral packaging and producer cell lines for large-scale vector production and clinical application: improved safety and high titer.
    Sheridan PL; Bodner M; Lynn A; Phuong TK; DePolo NJ; de la Vega DJ; O'Dea J; Nguyen K; McCormack JE; Driver DA; Townsend K; Ibañez CE; Sajjadi NC; Greengard JS; Moore MD; Respess J; Chang SM; Dubensky TW; Jolly DJ; Sauter SL
    Mol Ther; 2000 Sep; 2(3):262-75. PubMed ID: 10985957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of replication competent retrovirus and lentivirus.
    Sastry L; Cornetta K
    Methods Mol Biol; 2009; 506():243-63. PubMed ID: 19110631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Replicating retroviral vectors mediating continuous production and secretion of therapeutic gene products from cancer cells.
    Finger C; Sun Y; Sanz L; Alvarez-Vallina L; Buchholz CJ; Cichutek K
    Cancer Gene Ther; 2005 May; 12(5):464-74. PubMed ID: 15692609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of a semi-replicative gene delivery system allowing propagation of complementary defective retroviral vectors.
    Trajcevski S; Solly SK; Frisén C; Trenado A; Cosset FL; Klatzmann D
    J Gene Med; 2005 Mar; 7(3):276-87. PubMed ID: 15515136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highly efficient gene delivery for bladder cancers by intravesically administered replication-competent retroviral vectors.
    Kikuchi E; Menendez S; Ozu C; Ohori M; Cordon-Cardo C; Logg CR; Kasahara N; Bochner BH
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4511-8. PubMed ID: 17671137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene therapy-based treatment for HIV-positive patients with malignancies.
    Kang EM; De Witte M; Malech H; Morgan RA; Carter C; Leitman SF; Childs R; Barrett AJ; Little R; Tisdale JF
    J Hematother Stem Cell Res; 2002 Oct; 11(5):809-16. PubMed ID: 12427287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical protocol. A phase 1 open-label clinical trial of the safety and tolerability of single escalating doses of autologous CD4 T cells transduced with VRX496 in HIV-positive subjects.
    MacGregor RR
    Hum Gene Ther; 2001 Nov; 12(16):2028-9. PubMed ID: 11727736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.